Israeli Startup FIZE Medical Launches Early Kidney Disease Detection Device with Advanced Fluid Monitoring Technology

FIZE Medical is an Israeli medtech startup that offers the FIZE-kUO, a groundbreaking device, anchoring FIZE’s fluid management platform technology, detects early signs of kidney deterioration. The firm raised $14 million in a Series A-4 funding round, led by Rapha Capital Management and its managed fund, Rapha Capital PE Life Sciences Fund VI, bringing total Series A funding to $29 million.

Critically ill patients present a significant hemodynamic management challenge in intensive care units (ICUs). Misdiagnosis can have severe consequences and is a major contributor to ICU mortality. In the US, over 4 million patients are admitted to ICUs annually, with more than a third developing circulatory shock, a condition associated with a roughly 40% mortality rate. Furthermore, approximately half of all ICU patients develop acute kidney injury (AKI), which carries a mortality rate exceeding 20%. Early detection of both AKI and shock is crucial and has the potential to substantially reduce patient morbidity and mortality.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.

FIZE Medical is a commercial-stage company, solidifying its position as a pioneer in smart fluid management technology by expanding its geographical reach to the U.S., EU, and Asian markets. The company is also advancing its technological development and is set to soon launch AI-based predictive capabilities that will serve as a Decision Support System (DSS) through advanced data analysis. The market for AI-based technologies in critical care is currently estimated at approximately $12 billion annually.

FIZE Medical began with a chance conversation between Noam Levine, an aerodynamic measurement systems expert, and his neighbor, the head of a leading ICU, on the need for improved fluid management to prevent kidney deterioration and loss of life.

Surprised that manual urinometers were still in use, Levine saw that without precise measurement of fluid outputs, the whole fluid management system was at risk. The challenge was to develop an automated, digital platform that met (and exceeded) clinical goals.

What started as a challenge quickly became a vision. Levine founded FIZE Medical to develop the world’s first cost-effective technology platform for digital monitoring of urine output: the missing link in accurate and efficient patient fluid management.

Over the next year, FIZE Medical plans to expand its platform to include advanced AI-driven patient condition predictions, intra-abdominal pressure measurement, and additional features aimed at enhancing patient care.

“We are thrilled to have Rapha Capital as the lead investor in this funding round, reaffirming their commitment to our mission,” said Dror Zerem, CEO of FIZE Medical. “This funding, alongside support from Valitas Venture Capital, eHealth Ventures, and our existing investors, will enable us to accelerate our expansion into the U.S. and EU healthcare markets. With our innovative fluid management solutions, we look forward to positively impacting more hospitals and patients globally.”